Modern aspects of neuropathogenesis and neurological manifestations of COVID-19

Liudmyla A. Dziak*, O. S. Tsurkalenko, K. V. Chekha, V. M. Suk

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Coronavirus infection is a systemic pathology resulting in impairment of the nervous system. The involvement of the central nervous system in COVID-19 is diverse by clinical manifestations and main mechanisms. The mechanisms of interrelations between SARS-CoV-2 and the nervous system include a direct virus-induced lesion of the central nervous system, inflammatory-mediated impairment, thrombus burden, and impairment caused by hypoxia and homeostasis. Due to the multi-factor mechanisms (viral, immune, hypoxic, hypercoagulation), the SARS-CoV-2 infection can cause a wide range of neurological disorders involv-ing both the central and peripheral nervous system and end organs. Dizziness, headache, altered level of consciousness, acute cerebro-vascular diseases, hypogeusia, hyposmia, peripheral neuropathies, sleep disorders, delirium, neuralgia, myalgia are the most common signs. The structural and functional changes in various organs and systems and many neurological symptoms are determined to persist after COVID-19. Regardless of the numerous clinical reports about the neurological and psychiatric symptoms of COVID-19 as before it is difficult to determine if they are associated with the direct or indirect impact of viral infection or they are secondary to hypoxia, sepsis, cytokine reaction, and multiple organ failure. Penetrated the brain, COVID-19 can impact the other organs and systems and the body in general. Given the mechanisms of impairment, the survivors after COVID-19 with the infection penetrated the brain are more susceptible to more serious diseases such as Parkinson’s disease, cognitive decline, multiple sclerosis, and other autoimmune diseases. Given the multi-factor pathogenesis of COVID-19 resulting in long-term persistence of the clinical symptoms due to impaired neuroplasticity and neurogenesis followed by cholinergic deficiency, the usage of Neuroxon® 1000 mg a day with twice-day dosing for 30 days. Also, a long-term follow-up and control over the COVID-19 patients are recommended for the prophylaxis, timely determination, and correction of long-term complications.

Original languageEnglish
Pages (from-to)6-15
Number of pages10
JournalInternational Neurological Journal (Ukraine)
Issue number2
Publication statusPublished - 19 May 2021
Externally publishedYes


  • COVID-19
  • inflammatory response
  • neuroinflammation
  • neuroinvasion
  • neurologic complications
  • neurotropy
  • protein S
  • SARS-CoV-2


Dive into the research topics of 'Modern aspects of neuropathogenesis and neurological manifestations of COVID-19'. Together they form a unique fingerprint.

Cite this